NASDAQ:CYTR - CytRx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.65 -0.03 (-4.41 %) (As of 11/15/2018 06:25 AM ET)Previous Close$0.68Today's Range$0.64 - $0.6852-Week Range$0.64 - $2.47Volume192,100 shsAverage Volume253,007 shsMarket Capitalization$23.80 millionP/E Ratio-0.43Dividend YieldN/ABeta2.24 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California. Receive CYTR News and Ratings via Email Sign-up to receive the latest news and ratings for CYTR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYTR Previous Symbol CUSIPN/A Webwww.cytrx.com Phone310-826-5648 Debt Debt-to-Equity RatioN/A Current Ratio3.06 Quick Ratio3.06 Price-To-Earnings Trailing P/E Ratio-0.43 Forward P/E Ratio-1.59 P/E GrowthN/A Sales & Book Value Annual Sales$100,000.00 Price / Sales218.66 Cash FlowN/A Price / CashN/A Book Value$0.66 per share Price / Book0.98 Profitability EPS (Most Recent Fiscal Year)($1.52) Net Income$-34,980,000.00 Net MarginsN/A Return on Equity-68.26% Return on Assets-35.32% Miscellaneous Employees20 Outstanding Shares33,640,000Market Cap$23.80 million OptionableOptionable CytRx (NASDAQ:CYTR) Frequently Asked Questions What is CytRx's stock symbol? CytRx trades on the NASDAQ under the ticker symbol "CYTR." When did CytRx's stock split? How did CytRx's stock split work? Shares of CytRx reverse split before market open on Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 31st 2017. An investor that had 100 shares of CytRx stock prior to the reverse split would have 17 shares after the split. How were CytRx's earnings last quarter? CytRx Co. (NASDAQ:CYTR) released its earnings results on Friday, November, 9th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. The biotechnology company had revenue of $0.25 million for the quarter. View CytRx's Earnings History. When is CytRx's next earnings date? CytRx is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for CytRx. What price target have analysts set for CYTR? 1 Wall Street analysts have issued twelve-month price targets for CytRx's stock. Their predictions range from $5.00 to $5.00. On average, they anticipate CytRx's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 669.2% from the stock's current price. View Analyst Price Targets for CytRx. What is the consensus analysts' recommendation for CytRx? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytRx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytRx. What are Wall Street analysts saying about CytRx stock? Here are some recent quotes from research analysts about CytRx stock: 1. According to Zacks Investment Research, "CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies. " (11/7/2018) 2. HC Wainwright analysts commented, "Our price target is based on a composite valuation assessment that ascribes: (1) $105M to the future royalty streams from sales of aldoxorubicin, to which we assign a 60% probability of success and 12% discount rate; and (2) $55M to the LADR portfolio of candidates, which includes the companion diagnostic platform." (11/5/2018) Has CytRx been receiving favorable news coverage? Press coverage about CYTR stock has trended somewhat positive on Thursday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CytRx earned a news sentiment score of 1.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. Who are some of CytRx's key competitors? Some companies that are related to CytRx include BioCardia (BCDA), Aevi Genomic Medicine (GNMX), Aptose Biosciences (APTO), Oncobiologics (ONS), Brainstorm Cell Therapeutics (BCLI), Entera Bio (ENTX), Genocea Biosciences (GNCA), Curis (CRIS), TRACON Pharmaceuticals (TCON), BIONDVAX PHARMA/S (BVXV), Proteon Therapeutics (PRTO), Vical (VICL), Arsanis (ASNS), Genetic Technologies (GENE) and aTyr Pharma (LIFE). Who are CytRx's key executives? CytRx's management team includes the folowing people: Mr. Steven A. Kriegsman, Chairman & CEO (Age 76)Mr. John Y. Caloz, Chief Financial Officer (Age 66)Dr. Felix Kratz Ph.D., Sr. VP, Drug Devel. (Age 55)Mr. Eric L. Curtis M.B.A., Pres & COO (Age 50)Dr. André Warnecke Ph.D., Sr. Director of Drug Discovery How do I buy shares of CytRx? Shares of CYTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CytRx's stock price today? One share of CYTR stock can currently be purchased for approximately $0.65. How big of a company is CytRx? CytRx has a market capitalization of $23.80 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-34,980,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. CytRx employs 20 workers across the globe. What is CytRx's official website? The official website for CytRx is http://www.cytrx.com. How can I contact CytRx? CytRx's mailing address is 11726 SAN VICENTE BOULEVARD SUITE 650, LOS ANGELES CA, 90049. The biotechnology company can be reached via phone at 310-826-5648 or via email at [email protected] MarketBeat Community Rating for CytRx (NASDAQ CYTR)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 304 (Vote Outperform)Underperform Votes: 211 (Vote Underperform)Total Votes: 515MarketBeat's community ratings are surveys of what our community members think about CytRx and other stocks. Vote "Outperform" if you believe CYTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/15/2018 by MarketBeat.com StaffFeatured Article: What is a Fiduciary?